India and the WHO Pandemic Agreement: Equity, Pathogen Sharing and Preparedness
Revise the static topic: UPSC Social Justice notes · UPSC Science & Technology notes
In short: According to the supplied editorial, India backed equitable access to pandemic products and respect for national sovereignty at the UN High-Level Meeting in September 2026. The WHO Pandemic Agreement was adopted in 2025, but its opening for ratification awaits negotiations on the Pathogen Access and Benefit-Sharing annex. India's central challenge is to turn its pharmaceutical capacity and diplomatic influence into reciprocal commitments on pathogen sharing, access to technology and affordable medical products.
Why in news
India's remarks on the Political Declaration on Pandemic Prevention, Preparedness and Response have brought its role in global health governance into focus. Pending negotiations on pathogen access and benefit-sharing will shape whether the Pandemic Agreement delivers equity in practice.
124
Member-states supporting adoption, as reported
11
Member-states abstaining, as reported
Background
Pandemics cross borders, but health-system capacity, manufacturing capabilities and access to medical technologies remain unevenly distributed. The World Health Organization is the United Nations specialised agency for international health. The International Health Regulations provide an existing framework for managing public-health risks with potential international spread. The Pandemic Agreement seeks to strengthen cooperation on prevention, preparedness and response, including equitable access to pandemic-related health products. Its central governance challenge is to reconcile national decision-making with collective action against transboundary health threats.
What has happened: adoption without operational completion
The supplied editorial reports that the WHO Pandemic Agreement was adopted in 2025 with India's support and no vote against it. However, negotiations on the Pathogen Access and Benefit-Sharing system remain unfinished, and the agreement is not yet open for ratification.
Adoption, ratification and entry into force are distinct legal stages. Adoption settles the negotiated text at that stage; it does not by itself mean that an agreement is in force or that its proposed mechanisms are operational. The UN political declaration must also be distinguished from the treaty process.
- India has emphasised equitable access to vaccines, medicines and therapeutics alongside the primacy of member-states in shaping national responses.
- The unresolved annex is central to the agreement's equity promise, rather than merely a technical detail.
- Implementation will depend on workable arrangements for financing, technology access, manufacturing and accountability.
Infographic
Equitable access
Affordable and timely vaccines, medicines and therapeutics.
Reciprocal PABS
Connect pathogen access with credible benefit-sharing.
Funded preparedness
Back One Health, laboratories and workforce capacity.
Technology capability
Strengthen know-how, production and supply-chain resilience.
Country ownership
Combine national policy space with accountable cooperation.
AI-assisted infographic by Pragnya IAS Academy, based on the cited sources.
PABS: linking pathogen access with equitable benefits
Pathogen sharing supports surveillance, research and the development of diagnostics, vaccines and treatments. Yet countries providing biological material may lack the purchasing power or production capacity to obtain the resulting products promptly.
PABS seeks to connect access to pathogens with benefit-sharing. The editorial identifies fair access to vaccines, medicines and therapeutics for low- and middle-income countries as a key potential outcome. Specific allocation formulas, manufacturer obligations and enforcement arrangements should not be treated as settled while negotiations continue.
- Reciprocity requires countries contributing to global health security to share in the benefits generated from that cooperation.
- Affordability matters alongside availability: products that exist but cannot be purchased do not deliver meaningful access.
- Transparent access rules and credible benefit-sharing could build trust and encourage timely cooperation.
The sovereignty–solidarity bargain
The editorial shows that sovereignty concerns cut across the Global North–South divide. African countries resisted commitments to monitor the human–animal–environment interface without adequate funding, while countries in the Global North resisted binding technology-transfer targets.
India's approach is to combine national policy space with demonstrable international cooperation. Sovereignty need not mean isolation: agreed international rules can improve domestic preparedness when they respect national circumstances and are backed by resources.
- One Health obligations need financing, trained personnel and coordination across health, veterinary and environmental institutions.
- Technology cooperation must address practical manufacturing capabilities, not merely formal access to information.
- A framework that demands surveillance cooperation without credible access benefits risks weakening trust.
India's dual stake: major producer and access-dependent country
India's large pharmaceutical and vaccine manufacturing base gives it leverage in pandemic diplomacy, but production capacity is not the same as technological autonomy. The editorial highlights dependence on externally held vaccine patents, imported active pharmaceutical ingredients and access to advanced technologies for medical devices and high-grade protective equipment.
India therefore has an interest in predictable global distribution arrangements as well as stronger domestic capabilities. Its digital health infrastructure, laboratory networks and One Health initiatives can support South–South cooperation, provided cooperation is adapted to partner-country needs.
The strongest diplomatic strategy is to align external demands with domestic practice. Fair rules for access to biological material and benefit distribution would strengthen India's credibility when seeking similar standards internationally.
- Build technical partnerships on surveillance, workforce development and One Health.
- Use established multilateral platforms to connect equity commitments with implementation resources.
- Combine domestic supply-chain resilience with technology partnerships and regional capacity-building.
| Issue | Core tension | India's interest |
|---|---|---|
| Pathogen access | Timely sharing versus concerns over control and unequal returns | Trusted sharing arrangements linked to credible benefits |
| Medical-product access | Global need versus unequal purchasing and manufacturing capacity | Affordable, timely access during emergencies |
| Technology transfer | Wider production versus reluctance to accept binding commitments | Access to technology and manufacturing know-how |
| One Health | Prevention commitments versus inadequate implementation resources | Funded, nationally workable cross-sectoral cooperation |
| National sovereignty | Domestic policy space versus coordinated international action | Country ownership within a predictable multilateral framework |
- 1. Countries cooperate in providing access to pathogens under agreed rules.
- 2. Research and development use shared material to advance pandemic-related health products.
- 3. Agreed benefit-sharing arrangements connect access to resulting benefits.
- 4. Countries receive fairer access to vaccines, medicines and therapeutics.
- 5. Credible reciprocity strengthens trust and future preparedness cooperation.
2023
The editorial identifies the Global Initiative for Digital Health, launched during India's G20 presidency, as a platform relevant to India's health diplomacy.
2025
The WHO Pandemic Agreement was adopted with India's support, according to the supplied source.
September 2026
The editorial reports India's remarks at the UN High-Level Meeting in New York on pandemic prevention, preparedness and response.
Status reported in the editorial
PABS annex negotiations remain ongoing; the agreement is not yet open for ratification.
Significance, challenges & way forward
Significance
- Equitable access can reduce the gap between scientific breakthroughs and their availability in countries with weaker purchasing power.
- Reciprocal pathogen-sharing arrangements can align national incentives with collective health security.
- India can act as a bridge between manufacturing interests, technology holders and countries facing severe access constraints.
- Funded One Health cooperation can strengthen prevention across the human–animal–environment interface.
- An effective global framework can reinforce India's domestic preparedness rather than substitute for it.
Challenges
- Unresolved PABS negotiations leave the agreement's central equity mechanism incomplete.
- Sovereignty concerns can obstruct cooperation when obligations are perceived as externally imposed or unevenly distributed.
- Unfunded surveillance and prevention commitments can overburden fragile health systems.
- Patents, limited access to know-how and supply-chain dependencies can constrain the expansion of production.
- Manufacturing capacity alone cannot guarantee fair allocation during a global emergency.
- Domestic inconsistency in biological-material access and benefit-sharing could weaken India's negotiating credibility.
Way forward
- India should seek clear, reciprocal PABS rules that connect timely pathogen access with meaningful and affordable benefits.
- Negotiators should pair prevention and surveillance expectations with predictable finance and capacity-building support.
- Technology partnerships should include know-how, workforce training and regulatory capacity alongside licensing arrangements.
- India should align domestic biological-material access and benefit-sharing policies with the equity standards it advocates globally.
- South–South partnerships should prioritise practical cooperation in laboratories, One Health and health-workforce development.
- India should promote transparent implementation review while preserving legitimate national policy space.
Key terms
- Pandemic Prevention, Preparedness and Response
- The continuum of actions to reduce outbreak risks, build readiness and manage pandemic impacts.
- Pathogen Access and Benefit-Sharing
- A proposed system linking access to pathogens with fair sharing of resulting benefits, including medical products.
- One Health
- An integrated approach recognising the interdependence of human, animal and ecosystem health.
- Active Pharmaceutical Ingredient
- The component of a medicine responsible for its intended pharmacological action.
- Technology transfer
- Sharing technology, skills and manufacturing know-how needed to enable another entity to produce or use a product.
- Ratification
- An international act through which a state establishes its consent to be bound by a treaty, following applicable procedures.
- South–South cooperation
- Cooperation among developing countries through exchanges of knowledge, technology, resources and capabilities.
Link with static syllabus
Prelims practice MCQs
Q1. With reference to the WHO Pandemic Agreement as described in the supplied editorial, consider the following statements: 1. India supported its adoption. 2. Negotiations on the PABS annex have been completed. 3. Adoption necessarily means that a treaty has entered into force. Which of the statements given above is/are correct?
Q2. The central purpose of the proposed Pathogen Access and Benefit-Sharing system is to:
Q3. Consider the following statements about One Health: 1. It recognises links between human, animal and ecosystem health. 2. Its implementation can require coordination across health, veterinary and environmental institutions. 3. It is confined to treatment in hospitals after an outbreak occurs. Which of the statements given above are correct?
Q4. Which of the following statements best describes India's constitutional framework concerning international agreements?
Mains practice questions
GS 2 · 15 marks · 250 words
India's pharmaceutical strength does not eliminate its vulnerability to inequitable pandemic responses. Discuss how India can reconcile national sovereignty with global solidarity under the WHO Pandemic Agreement.
Frequently asked questions
Is the WHO Pandemic Agreement already fully operational?
Not according to the supplied editorial. It reports that PABS annex negotiations remain unfinished and the agreement is not yet open for ratification.
Why does India need vaccine equity despite being a major manufacturer?
Manufacturing strength does not remove dependence on patents, inputs, technology or global allocation decisions. India therefore benefits from both stronger domestic capabilities and fair international access arrangements.
How is PABS different from pathogen sharing alone?
Pathogen sharing enables research and surveillance; PABS seeks to connect that access with fair sharing of resulting benefits. Its equity objective is to prevent contributing countries from being left without access to medical products.
What should India's main negotiating priority be?
India should seek a workable bargain linking pathogen access, equitable benefits, financing and technology cooperation while protecting legitimate national policy space.
Sources
Analysis prepared by the Pragnya IAS Academy current-affairs desk with AI assistance from the cited reports. Verify figures with the original sources.
Turn current affairs into marks
Join Pragnya IAS Academy's mentorship for daily answer-writing evaluation on stories like this.